CND Life Sciences is dedicated to advancing the diagnosis of neurodegenerative diseases through innovative diagnostic tools. The company has developed the Syn-One Test®, the first commercially available skin-based test that helps clinicians diagnose Parkinson’s disease and related disorders by detecting abnormal alpha-synuclein in skin samples. With a CLIA-certified and CAP-accredited lab, CND Life Sciences emphasizes high accuracy, achieving over 95% sensitivity and specificity in its tests. The company is supported by multiple NIH-SBIR grants and has established research agreements with various biopharmaceutical companies, positioning itself as a leader in cutaneous neurodiagnostics and enhancing patient care through reliable diagnostic technologies.
Something looks off?On-site & Remote